Skip to content

Canadian Nanomedicine Expertise Database

To facilitate collaboration and resource sharing within the Canadian nanomedicine research community, NMIN is pleased to provide this searchable database of nanomedicine-related expertise among established/independent Canadian professionals.

The database includes Canadian academic faculty at least at the assistant professor level, as well as other Canadian professionals in academia, industry, or regulatory agencies who have passed their probationary period. If you meet these criteria and wish to be included in the database, please provide us your information here.

The table below can be searched by any field.

Search:
AllInstitutionResearcherNanodelivery typeTargeting approachApplicationDisease modelProtocolsInstrumentationAuxilliary expertise

Researcher: Theresa M Allen

Institution: University of Alberta / University of British Columbia (UBC)

Nanodelivery type

  • Lipid-based
  • Polymer-based

Targeting approach

  • Active targeting: Antibody or antibody fragments; Peptide; Small molecule
  • Physical targeting: pH sensitive

Application

  • Drug delivery: Soluble molecules; Insoluble molecules
  • Gene delivery: mRNA/samRNA; ASO
  • Peptide/protein delivery

Disease model(s)

  • Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)

Protocols: Safety/pharmacology

University of Alberta / University of British Columbia (UBC)

Theresa M Allen

Lipid-based

Polymer-based

Active targeting: Antibody or antibody fragments; Peptide; Small molecule

Physical targeting: pH sensitive

Drug delivery: Soluble molecules; Insoluble molecules

Gene delivery: mRNA/samRNA; ASO

Peptide/protein delivery

Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)

Safety/pharmacology

Researcher: Ildiko Badea

Institution: University of Saskatchewan

Nanodelivery type

  • Lipid-based
  • Inorganic

Targeting approach

  • Physical targeting: pH sensitive

Application

  • Drug delivery
  • Gene delivery: DNA, siRNA
  • Peptide/protein delivery

Disease model(s)

  • Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model)

Instrumentation: Synchrotron techniques

Auxiliary expertise: Other: Human research ethics

University of Saskatchewan

Ildiko Badea

Lipid-based Inorganic

Physical targeting: pH sensitive

Drug delivery
Gene delivery: DNA, siRNA
Peptide/protein delivery

Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model)

Synchrotron techniques

Other: Human research ethics

Researcher: Marc A Gauthier

Institution: Institut National de la Recherche Scientifique

Nanodelivery type

  • Polymer-based

Targeting approach

  • Active Targeting: Antibody or antibody fragments; Peptide; Aptamer
  • Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.)

Application

  • Drug delivery: Soluble molecules
  • Peptide/protein delivery

Disease model(s)

  • Cancer (In vitro, In vivo xenograft model, Primary cells)
  • Other: several diseases (In vitro, In vivo)

Auxiliary expertise: Non-nano delivery systems

Institut National de la Recherche Scientifique

Marc A Gauthier

Polymer-based

Active Targeting: Antibody or antibody fragments; Peptide; Aptamer
Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.)

Drug delivery: Soluble molecules
Peptide/protein delivery

Cancer (In vitro, In vivo xenograft model, Primary cells)

Other: several diseases (In vitro, In vivo)

Non-nano delivery systems

Researcher: Ken Harder

Institution: University of British Columbia (UBC)

Nanodelivery type

  • Lipid-based

Targeting approach

  • Other: 5 or 6 component LNPs for immune cell specific targeting

Application

  • Gene delivery: mRNA/samRNA

Disease model(s)

  • Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model)
  • Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models)

Protocols: Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting

Instrumentation: CyTOF

Auxiliary expertise: Non-nano delivery systems

University of British Columbia (UBC)

Ken Harder

Lipid-based

Other: 5 or 6 component LNPs for immune cell specific targeting

Gene delivery: mRNA/samRNA

Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model)

Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models)

Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting

CyTOF

Non-nano delivery systems

Researcher: Umar Iqbal

Institution: National Research Council of Canada

Nanodelivery type

  • Lipid-based

Targeting approach

  • Active targeting: Antibody or antibody fragments; Peptide
  • Physical targeting: Other (novel lipids and new lipid chemistry)

Application

  • Gene delivery: mRNA/samRNA; ASO

Disease model(s)

  • Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human)
  • Rare diseases (Human)

Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics

National Research Council of Canada

Umar Iqbal

Lipid-based

Active targeting: Antibody or antibody fragments; Peptide

Physical targeting: Other (novel lipids and new lipid chemistry)

Gene delivery: mRNA/samRNA; ASO

Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human)

Rare diseases (Human)

Safety/pharmacology (Pre-GLP toxicity); Microfluidics

Researcher: Jessica Kalra

Institution: University of British Columbia (UBC)

Nanodelivery type

  • Lipid-based

Application

  • Drug delivery: Soluble molecules; Insoluble molecules

Disease model(s)

  • Cancer (In vitro, Organoid)
  • Other: Neurological and inflammatory disease (In vitro, Organoid)

Protocols: Microfluidics

Auxiliary expertise: Other: In vivo modelling and imaging

University of British Columbia (UBC)

Jessica Kalra

Lipid-based

Drug delivery: Soluble molecules; Insoluble molecules

Cancer (In vitro, Organoid)

Other: Neurological and inflammatory disease (In vitro, Organoid)

Microfluidics

Other: In vivo modelling and imaging

Researcher: Sherry Leung

Institution: Precision NanoSystems

Nanodelivery type

  • Lipid-based

Targeting approach

  • Gene delivery

Protocols: Microfluidics

Precision NanoSystems

Sherry Leung

Lipid-based

Gene therapy

Microfluidics

Researcher: Shyh-Dar Li

Institution: University of British Columbia (UBC)

Nanodelivery type

  • Lipid-based
  • Polymer-based

Targeting approach

  • Other: EPR effect, protein corona

Application

  • Drug delivery: Soluble molecules; Insoluble molecules
  • Gene delivery: DNA, siRNA, mRNA/samRNA, ASO
  • Peptide/protein delivery

Disease model(s)

  • Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)
  • Rare diseases (In vivo: cancer, genetic diseases)
  • Diabetes (In vivo: STZ induced)

Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics

University of British Columbia (UBC)

Shyh-Dar Li

Lipid-based
Polymer-based

Other: EPR effect, protein corona

Drug delivery: Soluble molecules; Insoluble molecules
Gene delivery: DNA, siRNA, mRNA/samRNA, ASO
Peptide/protein delivery

Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)
Rare diseases (In vivo: cancer, genetic diseases)
Diabetes (In vivo: STZ induced)

Safety/pharmacology (Pre-GLP toxicity)
Microfluidics

Researcher: Michel Meunier

Institution: Polytechnique Montreal

Nanodelivery type

  • Lipid-based
  • Inorganic

Targeting approach

  • Active targeting: Antibody or antibody fragments
  • Physical targeting: Light sensitive

Application

  • Drug delivery: Soluble molecules
  • Gene delivery: siRNA, mRNA/samRNA

Disease model(s)

  • Cancer (In vitro)
  • Other: ophthalmology (In vitro)
Polytechnique Montreal

Michel Meunier

Lipid-based

Inorganic

Active targeting: Antibody or antibody fragments

Physical targeting: Light sensitive

Drug delivery: Soluble molecules

Gene delivery: siRNA, mRNA/samRNA

Cancer (In vitro)

Other: ophthalmology (In vitro)

Researcher: Raymond Reilly

Institution: University of Toronto

Nanodelivery type

  • Inorganic

Targeting approach

  • Other: Local intratumoural infusion or implantation of gold nanoparticles

Application

  • Other: Radioisotope delivery

Disease model(s)

  • Cancer (In vitro)

Protocols: Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing

Instrumentation: Radioisotope measurement and small animal imaging systems (SPECT and PET)

Auxiliary expertise: Regulatory science

University of Toronto

Raymond Reilly

Inorganic

Other: Local intratumoural infusion or implantation of gold nanoparticles

Other: Radioisotope delivery

Cancer (In vitro)

Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing

Radioisotope measurement and small animal imaging systems (SPECT and PET)

Regulatory science

Researcher: Manish Sadarangani

Institution: University of British Columbia (UBC)

Nanodelivery type

  • Other: bacterial outer membrane vesicles

Targeting approach

  • Active targeting: Antibody or antibody fragments

Application

  • Other: vaccine delivery

Disease model(s)

  • Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2)

Auxiliary expertise: Regulatory science

University of British Columbia (UBC)

Manish Sadarangani

Other: bacterial outer membrane vesicles

Active targeting: Antibody or antibody fragments

Other: vaccine delivery

Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2)

Regulatory science

Researcher: Gilbert Walker

Institution: University of Toronto

Nanodelivery type

  • Lipid-based
  • Polymer-based

Targeting approach

  • Active targeting: Antibody or antibody fragments; Small molecule
  • Physical targeting: pH sensitive

Application

  • Drug delivery: Soluble molecules; Insoluble molecules
  • Gene delivery: siRNA, ASO
  • Nano-imaging: Diagnostics

Disease model(s)

  • Cancer (In vitro)
  • Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent])

Protocols: Microfluidics

Instrumentation: high resolution mechanical and IR imaging

University of Toronto

Gilbert Walker

Lipid-based
Polymer-based

Active targeting: Antibody or antibody fragments; Small molecule
Physical targeting: pH sensitive

Drug delivery: Soluble molecules; Insoluble molecules
Gene delivery: siRNA, ASO
Nano-imaging: Diagnostics

Cancer (In vitro)
Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent])

Microfluidics

high resolution mechanical and IR imaging

Researcher: Xiao Yu (Shirley) Wu

Institution: University of Toronto

Nanodelivery type

  • Polymer-based
  • Other: Polymer-lipid hybrid, polymer-lipid-inorganic based

Targeting approach

  • Active targeting: Antibody or antibody fragments; Peptide; Small molecule
  • Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers)

Application

  • Drug delivery: Soluble molecules; Insoluble molecules
  • Gene delivery: DNA, siRNA, mRNA/samRNA, ASO
  • Peptide/protein delivery
  • Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI)

Disease model(s)

  • Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)
  • Diabetes (In vitro, In vivo: diabetic rats/mice)
  • Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models)

Protocols: Safety/pharmacology

Auxiliary expertise: Non-nano delivery systems

University of Toronto

Xiao Yu (Shirley) Wu

Polymer-based
Other: Polymer-lipid hybrid, polymer-lipid-inorganic based

Active targeting: Antibody or antibody fragments; Peptide; Small molecule
Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers)

Drug delivery: Soluble molecules; Insoluble molecules
Gene delivery: DNA, siRNA, mRNA/samRNA, ASO<
Peptide/protein delivery
Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI)

Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)
Diabetes (In vitro, In vivo: diabetic rats/mice)
Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models)

Safety/pharmacology

Non-nano delivery systems